Skip to main content
. Author manuscript; available in PMC: 2015 Apr 23.
Published in final edited form as: Drug Metabol Drug Interact. 2014;29(3):179–190. doi: 10.1515/dmdi-2013-0062

Figure 4.

Figure 4

Concentration-dependent uptake of TKIs in OATP-1B3 transfected CHO cells.

(A) Concentration-dependent uptake of canertinib in OATP-1B3 transfected CHO cells. OATP-1B3 mediated canertinib transport determined as the difference in uptake in OATP-1B3 and WT CHO cells at each substrate concentration. (B) Concentration-dependent uptake of nilotinib in OATP-1B3 transfected CHO cells. OATP-1B3 mediated nilotinib transport determined as the difference in uptake in OATP-1B3 and WT CHO cells at each substrate concentration. (C) Concentration-dependent uptake of vandetanib in OATP-1B3 transfected CHO cells. OATP-1B3 mediated vandetanib transport determined as the difference in uptake in OATP-1B3 and WTCHO cells at each substrate concentration. (D) Concentration-dependent uptake of pazopanib in WT and OATP-1B3 transfected CHO cells. (E) Concentration-dependent uptake of erlotinib in WT and OATP-1B3 transfected CHO cells. Each data point is expressed as mean±SD, n=4.